Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAmortizatization of IntangiblesCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation & Amortization (CF)Free Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Contineum Therapeutics (CTNM) Change in Accured Expenses (2023 - 2025)

Contineum Therapeutics has reported Change in Accured Expenses over the past 3 years, most recently at $2.1 million for Q4 2025.

  • Quarterly results put Change in Accured Expenses at $2.1 million for Q4 2025, down 28.62% from a year ago — trailing twelve months through Dec 2025 was -$516000.0 (down 122.41% YoY), and the annual figure for FY2025 was -$516000.0, down 122.41%.
  • Change in Accured Expenses for Q4 2025 was $2.1 million at Contineum Therapeutics, up from $351000.0 in the prior quarter.
  • Over the last five years, Change in Accured Expenses for CTNM hit a ceiling of $2.9 million in Q4 2024 and a floor of -$2.9 million in Q1 2025.
  • Median Change in Accured Expenses over the past 3 years was $124500.0 (2025), compared with a mean of $281750.0.
  • Biggest five-year swings in Change in Accured Expenses: skyrocketed 283.05% in 2024 and later plummeted 653.16% in 2025.
  • Contineum Therapeutics' Change in Accured Expenses stood at -$1.6 million in 2023, then skyrocketed by 283.05% to $2.9 million in 2024, then decreased by 28.62% to $2.1 million in 2025.
  • The last three reported values for Change in Accured Expenses were $2.1 million (Q4 2025), $351000.0 (Q3 2025), and -$102000.0 (Q2 2025) per Business Quant data.